参考文献
［1］中华医学会感染病学分会艾滋病丙型肝炎学组，中国疾病预防控制中心.中国艾滋病诊疗指南（2021年版）［J］.中华传染病杂志，2021，39（12）：715-735.
［2］世界卫生组织.艾滋病病毒［EB/OL］.（2022-11-01）［2023-07-25］.https：//www.who.int/zh/news-room/fact-sheets/detail/hiv-aids.
［3］卢洪洲，李太生.整合酶抑制剂临床应用专家共识［J］.中华临床感染病杂志，2018，11（6）：433-440.
［4］李见春，胡齐胜，高署，等.齐多夫定片剂人体生物等效性研究［J］.蚌埠医学院学报，2008，33（2）：217-219.
［5］肖婷，陈怡，汪淼，等.HIV-1非核苷类逆转录酶抑制剂的研究进展（2016-2021）［J］.中国药物化学杂志，2022，32（10）：786-809.
［6］Collier AC,Coombs RW,Schoenfeld DA,et al.Treatment of human immunodeficiency virus infection with saquinavir,zidovudine,and zalcitabine,AIDS Clinical Trials Group[J].N Engl J Med,1996.334（16）:1011-1017.
［7］周慧宇，朱梅，张国宁，等.新型HIV-1蛋白酶抑制剂的研究进展（2015～2019年）［J］.中国药物化学杂志，2020，30（7）：428-443-452.
［8］Deeks ED.Darunavir:a review of its use in the management of HIV-1 infection[J].Drugs,2014,74（1）:99-125.
［9］赵紫楠，郭思瑞，金鹏飞，等.蛋白酶抑制剂达芦那韦的研究进展［J］.中国合理用药探索，2020，17（6）：1-4.
［10］张仁芳，卢洪洲.含整合酶抑制剂抗HIV单片复方制剂与中国HIV感染者常见合并用药的相互作用及临床管理［J］.中国艾滋病性病，2021，27（9）：1036-1039.
［11］梁梦然，邹潇白，陈曦.HIV-1整合酶抑制剂的发展和基因耐药研究［J］.中国热带医学，2021，21（12）：1197-1216.
［12］Singh RK,Kumar S,Prasad DN,et al.Therapeutic journey of nitrogen mustard as alkylating anticancer agents:Historic to future perspectives[J].European journal of medicinal chemistry,2018,151:401-433.
［13］Chen XL,Liang MY,Wang D.Progress on the study of the mechanism of busulfan cytotoxicity[J].Cytotechnology,2018,70（2）:497-502.
［14］Seliger C,Nürnberg C,Wick W,et al.Lung toxicity of lomustine in the treatment of progressive gliomas[J].Neuro-oncology advances,2022,4（1）:vdac068.
［15］Oun R,Moussa YE,Wheate NJ.The side effects of platinum-based chemotherapy drugs:a review for chemists[J].Dalton transactions,2018,47（19）:6645-6653.
［16］广东省药学会.铂类药物临床应用与不良反应管理专家共识［J］.今日药学，2019，29（9）：577-585.
［17］Eng C,Jácome AA,Das P,et al.A PhaseⅡstudy of capecitabine/oxaliplatin with concurrent radiotherapy in locally advanced squamous cell carcinoma of the anal canal[J].Clinical colorectal cancer,2019,18（4）:301-306.
［18］Kang L,Tian Y,Xu S,et al.Oxaliplatin-induced peripheral neuropathy:clinical features,mechanisms,prevention and treatment[J].Journal of neurology,2021,268（9）:3269-3282.
［19］Liew YC,Tam YC,Oh CC.Treatments for AIDS/HIV-related Kaposi sarcoma:A systematic review of the literature[J].International journal of dermatology,2022,61（11）:1311-1324.
［20］Serretta V,ScaliciGesolfo C,Alonge V,et al.Mitomycin C from birth to adulthood.Urologia[J],2016,83（Suppl 2）:2-6.
［21］Freeman EE,McCann NC,Semeere A,et al.Evaluation of four chemotherapy regimens for treatment of advanced AIDS-associated Kaposi sarcoma in Kenya:a costeffectiveness analysis[J].The Lancet.Global health,2022,10（8）:e1179-e1188.
［22］Kciuk M,Marciniak B,Kontek R.Irinotecan-still an important player in cancer chemotherapy:A comprehensive overview[J].International journal of molecular sciences,2020,21（14）.
［23］Jiang R,Mei S,Zhao Z.Leucovorin（folinic acid）rescue for high-dose methotrexate:A review[J].Journal of clinical pharmacy and therapeutics,2022,47（9）:1452-1460.
［24］Requena C,Alsina M,Morgado-Carrasco D,et al.Kaposi sarcoma and cutaneous angiosarcoma:Guidelines for diagnosis and treatment[J].Actas dermo-sifiliograficas,2018,109（10）:878-887.
［25］王金万，孙燕，刘永煜，等.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究［J］.中国肺癌杂志，2005，8（4）：283-290.(https://www.daowen.com)
［26］Wherry EJ,Kurachi M.Molecular and cellular insights into T cell exhaustion.Nature reviews[J].Immunology,2015,15（8）:486-99.
［27］Stevanovi S,Pasetto A,Helman SR,et al.Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer[J].Science,2017,356（6334）:200-205.
［28］Thompson JA,Schneider BJ,Brahmer J,et al.Management of immunotherapyrelated toxicities,version 1.2022,NCCN clinical practice guidelines in oncology[J].Journal of the National Comprehensive Cancer Network:JNCCN,2022,20（4）:387-405.
［29］Puzanov I,Diab A,Abdallah K,et al.Managing toxicities associated with immune checkpoint inhibitors:consensus recommendations from the Society for Immunotherapy of Cancer（SITC）Toxicity Management Working Group[J].Journal for immunotherapy of cancer,2017,5（1）:95.
［30］Schneider BJ,Naidoo J,Santomasso BD,et al.Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy:ASCO guideline update[J].Journal of clinical oncology:official journal of the American Society of Clinical Oncology,2021,39（36）:4073-4126.
［31］Byeon S,Cho JH,Jung HA,et al.PD-1 inhibitors for non-small cell lung cancer patients with special issues:Real-world evidence[J].Cancer medicine,2020,9（7）:2352-2362.
［32］Spano JP,Veyri M,Gobert A,et al.Immunotherapy for cancer in people living with HIV:safety with an efficacy signal from the series in real life experience[J].AIDS,2019,33（11）:F13-f19.
［33］Zhang Y,Zhang Z.The history and advances in cancer immunotherapy:understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications[J].Cell Mol Immunol,2020,17（8）:807-821.
［34］Xu Y,Gao Z,Hu R,et al.PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy[J].J Immunother Cancer,2021,9（10）:e002699.
［35］Barclay J,Creswell J,Leon J.Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway[J].Arch Esp Urol,2018,71（4）:393-399.
［36］Grunwald V.T-cell checkpoint inhibitors in metastatic renal cell carcinoma[J].Curr Opin Urol,2015,25（5）:411-415.
［37］Sloan EA,Ring KL,Willis BC,et al.PD-L1 expression in mismatch repairdeficient endometrial carcinomas,including lynch syndrome-associated and MLH1 promoter hypermethylated tumors[J].Am J Surg Pathol,2017,41（3）:326-333.
［38］Xue G,Zheng N,Fang J,et al.Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells[J].Cancer Cell,2021,39（12）:1610-1622 e9.
［39］Guedan S,Ruella M,June CH.Emerging cellular therapies for cancer[J].Annu Rev Immunol,2019,37:145-171.
［40］Seliktar-Ofir S,Merhavi-Shoham E,Itzhaki O,et al.Selection of shared and neoantigen-reactive T cells for adoptive cell therapy Based on CD137 separation[J].Front Immunol,2017,8:1211.
［41］Butiuc-Keul A,Farkas A,Carpa R,et al.CRISPR-Cas system:The powerful modulator of accessory genomes in prokaryotes[J].Microb Physiol,2022,32（1-2）:2-17.
［42］Kaufman HL,Kohlhapp FJ,Zloza A.Oncolytic viruses:a new class of immunotherapy drugs[J].Nat Rev Drug Discov,2016,15（9）:660.
［43］Marelli G,Howells A,Lemoine NR,et al.Oncolytic viral therapy and the immune system:A double-edged sword against cancer[J].Front Immunol,2018,9:866.
［44］Ott PA,Wu CJ.Cancer vaccines:Steering T cells down the right path to eradicate tumors[J].Cancer Discov,2019,9（4）:476-481.
［45］Saxena M,van der Burg SH,Melief CJM,et al.Therapeutic cancer vaccines[J].Nat Rev Cancer,2021,21（6）:360-378.
［46］Liu J,Fu M,Wang M,et al.Cancer vaccines as promising immuno-therapeutics:platforms and current progress[J].J Hematol Oncol,2022,15（1）:28.
［47］Bonati L,Tang L.Cytokine engineering for targeted cancer immunotherapy[J].Curr Opin Chem Biol,2021,62:43-52.
［48］Chen X,Ai X,Wu C,et al.A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2[J].Cell Death Dis,2018,9（10）:989.
［49］Davar D,Ding F,Saul M,et al.High-dose interleukin-2（HD IL-2）for advanced melanoma:a single center experience from the University of Pittsburgh Cancer Institute[J].J Immunother Cancer,2017,5（1）:74.